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ABSTRACT | Cachexia has been known to physicians since ancient Greek times as a ‘signum mali ominis’ 
in various diseases indicating end stage disease and poor quality of life. Cardiac cachexia is recently 
receiving growing attention as modern treatment options prevent early death from cardiac events and 
more patients live with chronic compensated heart failure. Nevertheless, observation and clinical 
documentation of this condition go back as long as medical science itself. Pioneering studies on the 
reasons and mechanisms of cachexia were performed several decades ago. These studies provide 
fundamental insights and guidance towards a better understanding of cachexia. This review presents an 
overview of early thoughts and milestone studies on metabolic abnormalities and cachexia in chronic 
heart failure. 
KEYWORDS | Cachexia; Metabolic abnormalities; Chronic heart failure; History. 
 
1. Introduction 
Heart disease is today in the centre of medical 
attention. Within the last 50 years, therapeutic 
options have improved greatly. Since the 
introduction of the first mercury diuretics, the 
control of fluid balance became a cornerstone for 
cardiac therapy. Antibiotics, from the beginning, 
have been used to ameliorate deleterious effects 
of infections causing and/or aggravating valvular 
diseases. With increasing insight in the complex 
pathophysiology of the cardiovascular system, 
both powerful medical and interventional 
therapeutical options are now in our hands for the 
treatment of cardiac disease. As a result, fewer 
people die from an acute cardiac event or early in 
a decompensated state and an increasing number 
of patients are seen with longer lasting, 
compensated chronic heart failure. New problems 
emerged with this shift in the patient population 
and complications of late stage chronic heart 
failure are of rising importance. Cardiac cachexia is 
therefore increasingly recognised and the 
research interest in this complication of chronic 
heart failure is growing [1]. Cachexia is known to 
physicians for centuries as a ‘signum mali ominis’ 
indicating end stage disease and poor quality of 
life. Cardiac cachexia has been recognised by 
doctors in all times and early annotations can be 
found in the medical literature dating back as long 
as medical science itself. 
In this review we present a historic overview on 
cardiac cachexia from the first anecdotal 
documentation to the beginning of its systematic 
investigation. The material reviewed in the 
following is taken entirely from Western sources. 
We concentrated on material that was published 
prior to the start of the online library Medline and 
is mainly based on the Index Medicus which dates 
back as far as the 18th century (►Fig. 1). 
 
2. Early annotations 
The earliest report on significant weight loss in 
relation to what can be diagnosed as heart failure 
dates back 2400 years to classical Greece and the 
school of medicine of Hippocrates (about 460–377 
BC) on the island of Cos. Observing an association 
between dropsy and cachexia, Hippocrates wrote 
that ‘the flesh is consumed and becomes water,… 
the abdomen fills with water, the feet and legs 
swell, the shoulders, clavicles, chest and thighs 
melt away… This illness is fatal’ [2]. Hippocrates 
also recognised the severely impaired prognosis 
of this syndrome. The origin of the term ‘cardiac 
cachexia’ is also Greek: derived from the words 
kakós (i.e. bad) and hexis (i.e. condition or 
appearance). It was, however, to be established 
only many centuries later as no understanding of 
the physiology of the heart and the circulatory 
system existed in ancient Greece and the heart 
was in fact debated as being the location for the 
intellect. Regardless of the lack of understanding 
of the underlying reasons, these passages in the 
corpus Hippocratus provide almost the only high  
quality clinical records on cachexia for the next 
1700 years. 
When the term cardiac cachexia was first 
introduced into medical literature remains 
uncertain. The understanding of the physiological 
function of the heart was of course a prerequisite. 
In 1628 Harvey discovered the circulatory 
physiology and recognised the heart rightly 
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as the driving pump for the circular movement of 
the blood [3]. This finding replaced the then 
prevailing Galenic view of the heart generating 
and distributing pneuma and heat throughout the 
body [4]. Only now it was possible to link 
symptoms of a failing circulation with 
pathophysiological findings of the heart. A rather 
anecdotal case of what likely was cardiac cachexia 
was observed by Withering (1741–1799) in 1785. 
In his work ‘An Account of the Foxglove and some 
of its Medical Uses with Practical Remarks on 
Dropsy and other diseases’ (which was to 
introduce digitalis into modern medicine) he 
wrote about one of his patients ‘…his 
countenance was pale, his pulse quick and feeble, 
his body greatly emaciated, except his belly, 
which was very large’ [5]. The earliest written 
documentation of the term cardiac cachexia 
comes from Charles Mauriac, a French Physician. 
In his medical thesis, in 1860 he wrote of a 
‘commonly observed secondary phenomenon in 
patients affected with diseases of the heart… a 
peculiar state of cachexia which is 
…conventionally designated cardiac cachexia’ [6]. 
Similar observations were reported by others: 
‘Disease of the heart occasionally results in a 
certain picture of cachexia ‘Chachéxie cardiaque’ 
due to blood congestion etc. The ‘heart failure 
colour’ of some heart patients is known; a distinct 
livid paleness is indicative in many heart patients’ 
[7]. 
Apart from these rare reports, cardiac cachexia as 
a syndrome was not studied in much detail by 
clinical scientists for many years to come. If 
recorded, authors mostly did not extend their 
reports beyond the state of mere observation. 
Anorexia was known to accompany cardiac 
decompensation and the grave prognosis in those 
cases was well recognised. ‘…But other cases 
occur which are neither so frequent nor so well 
known; in these the exertion does not give rise to 
sudden death, but starts a slowly ingravescent 
asthenia from which there is no recovery’ [8]. 
However, potential mechanisms for this have not 
been explored in detail. Weakness and a reduced 
urge to eat were easily accepted as underlying 
mechanisms of weight loss. 
To understand the lack of interest in this 
syndrome it has to be viewed in the context and 
the background of the clinical setting in the 19th 
and the beginning of the 20th century. Cachexia 
was of course known to physicians as a severe 
clinical condition indicating both grossly reduced 
life quality and early death. It was, however, seen 
more in the context of diseases other than the 
failing heart, mainly in relation to severe 
undernutrition or as a very serious complication in 
diseases like tuberculosis, malignancies or 
uncontrolled metabolic disorders like diabetes 
mellitus or thyreotoxicosis. In comparison to those 
diseases, cardiac cachexia was a rather rare 
condition, simply because the vast majority of 
patients with heart failure would not reach the 
state of chronicity for cachexia to develop. No 
sufficient and practicable treatment to control for 
fluid overload was available and heart failure 
patients—mostly with valve diseases as the 
underlying aetiology—died early in the course of 
the disease in a state of acute decompensation. 
With the introduction of modern therapy it was 
possible to keep patients in stable, compensated 
condition for longer time periods. Only then have 
the lives of patients suffering from various forms 
of heart disease been prolonged considerably, and 
consequently new aspects of the disease emerged 
with the extended duration of the disease 
including a growing number of patients with 
cardiac cachexia. A shift in the perception of the 
disease occurred which is also expressed by the 
gradual change from the term congestive heart 
failure to the more commonly-used term chronic 
heart failure or chronic congestive heart failure in 
today’s literature. 
 
3. Franklin D Roosevelt: a case of cardiac 
cachexia 
The following case may illustrate that, beside the 
personal tragedy, fundamental historical 
implications may arise from certain cases of 
cardiac cachexia. When Franklin D. Roosevelt 
became President of the United States in 1935, he 
had been profoundly affected by poliomyelitis and 
he suffered from persistent hypertension. He was 
also being treated with digitalis for congestive 
heart failure. Shortly before the Yalta Conference 
(February 1945), it became evident that he had 
developed cardiac cachexia leaving the President 
with increasing weakness and fatigue at minimum 
exertion [9]. In their conference on post-war 
strategies for Europe, Churchill and Stalin were 
able to take advantage of Roosevelt’s poor health 
status. It has been commented that ‘…at the 
Conference, Roosevelt’s cerebral arteriosclerosis 
and reno-vascular hypertension and cardiac 
cachexia certainly affected his judgment, leading 
to the imposition of communism in Eastern 
Europe and Asia’ [10]. Thus, Roosevelt’s cardiac 
cachexia profoundly affected the outcome of the 
Yalta meeting, and the course of world history for 
the following decades. We are interested to learn 
more about famous cases of cardiac cachexia, and 
we would be happy if any reader with such 
information contacted us. 
 
Doehner W et al. 
 
 
MDC Repository | http://edoc.mdc-berlin.de/6228/ 3 
 
4. Pioneering studies 
The observation of major alterations in body 
composition that accompany chronic heart failure 
has been attributed commonly to anorexia, i.e. 
reduced eating. Voluntary reduction of food 
intake was even seen as a compensatory 
mechanism, to prevent the additional strain, that 
a large meal with the resulting increase in 
splanchnic blood flow may impose on the weak 
heart [11]. ‘The histories leave no doubt that 
anorexia is the chief cause of the malnutrition (in 
congestive heart failure), with nausea and 
vomiting frequently acting as contributory factors’ 
[12]. Although this view was widely accepted, 
quantitative data derived from balance studies are 
rare. In a small study on decompensated heart 
failure patients with anorexia, a negative nitrogen 
and caloric balance was found which became 
positive with recompensation and a voluntary 
increase in food intake [13]. The situation for 
patients with cardiac cachexia might have been 
worsened by the fact that often the caloric intake 
was further reduced by dietary restrictions 
imposed on any patient with heart failure by the 
physicians of that time. A restricted diet was 
widely accepted as beneficial for the ‘senile’ heart 
[14] and a variety of diets existed for that purpose. 
For example, the Karrel diet [15] was very popular 
for several decades, however—although salt 
restriction was a desired side effect—the 800 ml 
milk and nothing else that comprised Karrel’s 
prescription was less than satisfactory. 
Prospective studies on mechanisms of cardiac 
cachexia were rare in the first half of the 20th 
century for the reasons given above. There was, 
however, pioneering work done that provided the 
foundation for today’s knowledge of the 
pathophysiology of cardiac cachexia. Some of the 
current theories have their roots in the work that 
was done decades ago (►Table1), like for instance 
studies on hypoxia [16], subacute inflammation in 
HF [17] or upregulated sympathetic activation 
[18]. 
Several studies have shown a connection 
between cardiac congestion and impaired 
intestinal capacity for absorption of nutrients. As 
early as 1888 it was shown that in patients with 
congestive heart failure due to valvular defects, 
impairment of intestinal absorption can be 
measured. In this study, fat absorption was 
reduced by 18% whereas nitrogen and 
carbohydrate absorption were only marginally 
impaired [19]. This is very similar to what has been 
described by King et al. in two studies 107 years 
later [20 and 21]. In 1938 an Italian group found 
increased steatorrhea in 12 of 20 cases with 
oedematous cardiac patients [22]. In the early 
1960s several studies using I131-labelled fat 
administration gave further evidence of reduced 
fat absorption in congestive heat failure [23 and 
24]. The authors noted a correlation between 
severity of the congestion and the degree of 
steatorrhea as well as a reversion to normal fat 
absorption when compensation could be 
achieved. Those studies were based on the 
hypothesis that elevated venous pressure may 
cause congestive oedema of the intestinal wall 
which was indeed reported in 1943 [25]. Also, 
abnormal protein absorption was reported for 
heart failure patients with the finding of protein-
losing gastroenteropathy [26] contributing to 
reduced oncotic pressure and the production of 
cardiac oedema and impaired intestinal 
absorption of amino acids in oedematous patients 
[27]. 
Already at the beginning of the 19th century, 
physicians noted an important factor in the 
wasting process in chronic heart failure that could 
not be explained by simple reduction of caloric 
intake. It may serve as an example for the 
observational skills of these physicians that was 
the basis for many discoveries in times when 
today’s technology was not available: in contrast 
to uncomplicated starvation, where the energy 
expenditure is compensatorily decreased, an 
elevated metabolic rate was recognised in 
patients with heart failure. Several symptoms like 
tachycardia, hyperpnea, sweating and a rise in 
body temperature indicated an increase of the 
metabolic rate that stands in sharp contrast to the 
reduced energy supply in these patients [28]. In 
1916, the increase in the basal metabolic rate was 
directly documented [29 and 30]. Increased 
metabolic demands of several specific tissues 
were discussed as one underlying reason for this 
finding. Decreased efficiency of the respiratory 
system due to reduced compliance [31] and 
capacity of the lungs together with 
hyperventilation result in higher energy demands 
of the respiratory muscles [32]. It was also 
suggested that the hypertrophied myocardium 
may contribute to the hypermetabolism in chronic 
heart failure [33 and 34]. The combination of an 
increase in total energy consumption of the heart 
and reduced cardiac output [35] was viewed as 
diminished myocardial efficiency [36]. Enhanced 
erythropoietic activity and hyperplasia of red bone 
marrow has also been repeatedly demonstrated 
[37 and 38] and was also discussed to contribute 
to increased caloric turnover. 
In contrast to the increased metabolic demands of 
specific tissues, other abnormalities may produce 
a more generalised caloric effect. In this context, 
detailed studies revealed that elevated body 
temperature is a common finding in patients with 
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chronic heart failure. In two large studies in the 
1930s, the majority of patients with HF was found 
to have at least mildly elevated body temperature. 
In 1934, Cohen and Steel studied 300 cardiac 
patients for body temperature, measured rectal 
on two or more occasions [17]. In 172 of these 
patients heart failure was diagnosed. In this study, 
only 11% of the patients with heart failure had 
normal temperature but 89% had some degree of 
pyrexia. This came often from pneumonia or other 
infections. Other causes of inflammation, like 
thrombosis, pulmonal or myocardial infarctions, 
rheumatic activity and bacterial endocarditis were 
also diagnosed. Cohn and Steel also described a 
number of cases where the origin of the fever 
could not be established, mainly in those cases 
where temperature was only slightly elevated. In 
another study by Kinsey and White, out of 200 
patients only four were free of fever [39]. 
Inflammatory immune activation may have been 
the cause for the fever. Today, one hypothesis 
suggests that bowel wall oedema causes bacterial 
translocation [40] which may explain increased 
levels of endotoxin that are found in 
decompensated heart failure patients [41]. 
Already back in 1934, Cohn and Steel discussed 
the possibility of a yet unidentified pyrogen 
causing the higher temperature [17]. The accuracy 
and thoughtful interpretation of these old studies 
is stunning in the light of the more recent finding 
of mild but measurable immune activation in 
patients with chronic heart failure characterised 
by elevated TNF-alpha levels and other pro-
inflammatory cytokines [42 and 43]. 
The observation of constant ‘air hunger’ directed 
some research attention to the role of reduced 
oxygen supply to the tissue. The subject of cellular 
hypoxia became a focus of metabolic research 
already at the beginning of the 20th century. First 
blood gas analyses were reported as early as 1919 
[16], and in 1923 it was observed in studies at high 
altitudes that in thin air, study subjects would 
involuntarily lose weight [44]. Evidence for 
reduced tissue oxygen supply came mostly from 
indirect observations like increased erythropoietic 
activity and elevated lactate production. 
Increased lactate levels as a measure of an 
imbalance between aerobic and anaerobic 
metabolism were reported in the 1930s and 
repeatedly thereafter [45]. In 1958, Huckabee 
introduced the concept of ‘excess lactate’ 
production as a measure of tissue hypoxia [46]. It 
was estimated that in heart failure 25 to 50% of 
the body’s energy needs would be derived from 
anaerobic glycolysis [47]. In normal subjects, this 
study found that the anaerobic pathway would 
account for only 5% of the energy production 
during exercise. Those observations suggested 
that lack of oxygen at tissue levels reduces 
energetic efficiency but also negatively affects 
protein biosynthesis leading to down-regulated 
anabolic and increased catabolic pathways. 
Based on early observations of sweating, 
tachycardia, venoconstriction and systemic 
increased vascular resistance with reduced 
cutaneous and renal blood flow, an overactivity of 
the sympathetic nervous system was recognised. 
The finding of elevated norepinephrine levels in 
chronic heart failure patients by Chidsey et al. in 
1962 supported this hypothesis [18]. The authors 
recognised this as compensatory mechanism to 
improve cardiac performance. 
 
5. A complex picture emerges 
More work was done in the 1950s and 1960s to 
study special aspects of metabolic malfunction 
and altered body composition secondary to 
chronic heart failure. The evidence emerging from 
these studies made it apparent that multiple 
mechanisms act in combination forming a 
complex web of metabolic imbalance with 
catabolism dominating the anabolic drive and the 
consequence of weight loss. A first attempt for a 
comprehensive overview on the complex 
pathophysiology of cardiac cachexia was made by 
Pittman and Cohen in 1965 [48 and 49] (►Fig. 2). 
From their review of related studies, they 
addressed three main pathophysiologic 
mechanisms of cardiac cachexia: 
1. dietary factors, 
2. loss of potential nutrients, and 
3. abnormal metabolism of ingested food. 
To briefly summarise the findings of Pittman and 
Cohen: dietary factors, i.e. reduced supply of 
nutrients to the body, as discussed before, are 
generally accepted as a factor of primary 
importance in the genesis of cardiac cachexia. 
Many reasons for a reduced food intake in the 
setting of reduced cardiac function have been 
discussed. Patients frequently complain of 
gastrointestinal problems and a whole range of 
reasons were identified: reduced gastric motility, 
delayed gastric emptying, a reduced capacity due 
to hepatomegaly, ascitis, meteorism and pain due 
to distension or splanchnic angina. Also, 
psychological factors may account for reduced 
eating, like depression, fear of increased 
discomfort after a meal. In this context, also a 
change in the pattern of eating was discussed. 
Instead of eating a full meal three times per day, 
patients would start to eat small portions of food 
irregularly over long periods of the day. This 
‘nibbling’ instead of the normal ‘gorging’ has been 
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suggested to affect the intermediary metabolism 
and make the calorie uptake less efficient [50 and 
51]. An excessive loss of potential nutrients due to 
impaired absorption or excessive excretion has 
been shown for fat as well as for protein 
absorption and vitamins [52]. 
At the same time, an increased metabolic rate due 
to increased energetic demands of specific tissues 
and generalised caloric factors like increased body 
temperature may further contribute to an 
unfavourable balance of the body’s energy 
metabolism. As a result the catabolic drive may 
chronically dominate the anabolic pathways. The 
constant drain of the body’s energy reserves may 
eventually lead to a pathological degree of tissue 
degradation. 
More than a century of studying the phenomenon 
of cardiac cachexia has passed. Especially in the 
last decade, many specific aspects of this 
complication of chronic heart failure have been 
discovered [1]. The 19th century brought the 
medical term and the clinical recognition of 
cardiac cachexia, the 20th century focused on 
more sophisticated pathophysiologic studies of 
this subject. With regard to therapeutical options, 
however, cardiac cachexia still is an unknown and 
unconquered territory. In 1964 Pittman and 
Cohen conclude: ‘Besides the avoidance of… 
potentially harmful forms of therapy, the only 
known treatment of cardiac cachexia requires 
improvement in cardiac function’ [48]. This has 
not been amended until today. We believe, the 
21st century will see this therapy being 
developed. 
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►Fig.1. Timetable of printed indices for medical publications from the beginning until the start of the 
computerized online library Medline. 
Doehner W et al. 
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►Fig.2. Overview of the pathophysiologic mechanisms contributing to cardiac cachexia as suggested by 
Pittman and Cohen [48]. 
Doehner W et al. 
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